MedTrace Logo

Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases

NCT03656640 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2021-03-10

No results posted yet for this study

Summary

This observational trial assesses the safety and efficacy of Gammanorm® in autoimmune diseases.

Conditions

Interventions

DRUG

Gammanorm

Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care.

Sponsors & Collaborators

  • Octapharma

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-23
Primary Completion
2019-12-09
Completion
2019-12-09
FDA Drug
Yes

Countries

  • France
  • Martinique

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03656640 on ClinicalTrials.gov